Products
Maridebart Biosimilar Monoclonal Antibody (GIP Receptor) for Research
Cat No.: GMP-Bios-INN-1277
Anti-GIPR therapeutic antibody (Pre-made Maridebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Maridebart (development code AMG133, also known as MariTide) is a monoclonal antibody targeting GIPR. It is developed by Amgen for obesity. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1277-1mg | 1mg | 3090 |
| GMP-Bios-INN-1277-10mg | 10mg | |
| GMP-Bios-INN-1277-100mg | 100mg | |
| GMP-Bios-INN-1277-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Maridebart biosimilar, Whole mAb, Anti-GIPR Antibody: Anti-GIPR/Gastric inhibitory polypeptide receptor/GIP-R/Glucose-dependent insulinotropic polypeptide receptor therapeutic antibody |
| INN Name | Maridebart |
| Target | GIPR |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 6dkj:HL:BA |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Amgen |
| Conditions Approved | na |
| Conditions Active | Obesity |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
